Clinical Trial Update: Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety and functional imaging of cG250 with sunitinib in advanced renal cell carcinoma was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sunitinib (sunitinib)
• cG250

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Renal Cell Carcinoma (RCC) | Phase 1 | Status: TERMINATED | Results posted: 2021-06-16